» Articles » PMID: 30561127

German Cancer Consortium (DKTK) - A National Consortium for Translational Cancer Research

Abstract

The German Cancer Consortium ('Deutsches Konsortium für Translationale Krebsforschung', DKTK) is a long-term cancer consortium, bringing together the German Cancer Research Center (DKFZ), Germany's largest life science research center, and the leading University Medical Center-based Comprehensive Cancer Centers (CCCs) at seven sites across Germany. DKTK was founded in 2012 following international peer review and has positioned itself since then as the leading network for translational cancer research in Germany. DKTK is long term funded by the German Ministry of Research and Education and the federal states of each DKTK partner site. DKTK acts at the interface between basic and clinical cancer research, one major focus being to generate suitable multisite cooperation structures and provide the basis for including higher numbers of patients and facilitate effective collaborative forward and reverse translational cancer research. The consortium addresses areas of high scientific and medical relevance and develops critical infrastructures, for example, for omics technologies, clinical and research big data exchange and analysis, imaging, and clinical grade drug manufacturing. Moreover, DKTK provides a very attractive environment for interdisciplinary and interinstitutional training and career development for clinician and medical scientists.

Citing Articles

The Journey to a FAIR CORE DATA SET for Diabetes Research in Germany.

Inau E, Dedie A, Anastasova I, Schick R, Zdravomyslov Y, Frohlich B Sci Data. 2024; 11(1):1159.

PMID: 39433782 PMC: 11494036. DOI: 10.1038/s41597-024-03882-0.


Comparative analysis of integrative classification methods for multi-omics data.

Novoloaca A, Broc C, Beloeil L, Yu W, Becker J Brief Bioinform. 2024; 25(4).

PMID: 38985929 PMC: 11234228. DOI: 10.1093/bib/bbae331.


The German Network for Personalized Medicine to enhance patient care and translational research.

Illert A, Stenzinger A, Bitzer M, Horak P, Gaidzik V, Moller Y Nat Med. 2023; 29(6):1298-1301.

PMID: 37280276 DOI: 10.1038/s41591-023-02354-z.


Profile of the multicenter cohort of the German Cancer Consortium's Clinical Communication Platform.

Maier D, Vehreschild J, Uhl B, Meyer S, Berger-Thurmel K, Boerries M Eur J Epidemiol. 2023; 38(5):573-586.

PMID: 37017830 PMC: 10073785. DOI: 10.1007/s10654-023-00990-w.


Record linkage based patient intersection cardinality for rare disease studies using Mainzelliste and secure multi-party computation.

Kussel T, Brenner T, Tremper G, Schepers J, Lablans M, Hamacher K J Transl Med. 2022; 20(1):458.

PMID: 36209221 PMC: 9547637. DOI: 10.1186/s12967-022-03671-6.


References
1.
Celis J, Pavalkis D . A mission-oriented approach to cancer in Europe: a joint mission/vision 2030. Mol Oncol. 2017; 11(12):1661-1672. PMC: 5709667. DOI: 10.1002/1878-0261.12143. View

2.
Weller M, van den Bent M, Tonn J, Stupp R, Preusser M, Cohen-Jonathan-Moyal E . European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017; 18(6):e315-e329. DOI: 10.1016/S1470-2045(17)30194-8. View

3.
Eggermont A, Apolone G, Baumann M, Caldas C, Celis J, De Lorenzo F . Cancer Core Europe: A translational research infrastructure for a European mission on cancer. Mol Oncol. 2019; 13(3):521-527. PMC: 6396377. DOI: 10.1002/1878-0261.12447. View

4.
Worst B, van Tilburg C, Balasubramanian G, Fiesel P, Witt R, Freitag A . Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study. Eur J Cancer. 2016; 65:91-101. DOI: 10.1016/j.ejca.2016.06.009. View

5.
Ruda R, Reifenberger G, Frappaz D, Pfister S, Laprie A, Santarius T . EANO guidelines for the diagnosis and treatment of ependymal tumors. Neuro Oncol. 2017; 20(4):445-456. PMC: 5909649. DOI: 10.1093/neuonc/nox166. View